In the NK cell competent mice that are deficient in adaptive immunity (T cells and B cells), implanted c-MYC–driven murine neuroblastomas and human neuroblastoma xenograft models are completely eradicated by indisulam, suggesting that NK cells or innate immunity may play a critical role in indisulam-mediated anticancer activity. Here, MYC is linked to neuroblastoma.